Primary Care Diabetes
Volume 4 , Pages S31-S42 , April 2010

Insulin detemir: A historical perspective on a modern basal insulin analogue

  • Luigi Meneghini

      Affiliations

    • University of Miami Miller School of Medicine, Miami, Florida, USA
    • Corresponding Author InformationCorresponding author. Luigi Meneghini. Division of Endocrinology & Diabetes, University of Miami School of Medicine, Diabetes Research Institute, 1450 NW 10th Avenue, Miami, Florida 33136, USA. Tel.: +1 305-243-5366; fax: +1 305-243-1200
    • ,
  • Andreas Liebl

      Affiliations

    • Center for Diabetes and Metabolism, Fachklinik, Bad Heilbrunn, Germany
    • ,
  • Martin J. Abrahamson

      Affiliations

    • Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA

References 

  1. Bliss M . Resurrections in Toronto: the emergence of insulin . Horm. Res. . 2005;64(Suppl. 2):98–102
  2. Lindholm A . New insulins in the treatment of diabetes mellitus . Best Pract. Res. Clin. Gastroenterol. . 2002;16:475–492
  3. Emdin SO , Dodson GG , Cutfield JM , Cutfield SM . Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell . Diabetologia . 1980;19:174–182
  4. Hildebrandt P , Sejrsen P , Nielsen SL , et al.   Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients . Scand. J Clin. Lab. Invest. . 1985;45:685–690
  5. Kang S , Brange J , Burch A , et al.   Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans . Diabetes Care . 1991;14:942–948
  6. Polonsky KS , Given BD , van Cauter E . Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects . J. Clin. Invest. . 1988;81:442–448
  7. Hanefeld M , Fischer S , Julius U , et al.   Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up . Diabetologia . 1996;39:1577–1583
  8. Tominaga M , Eguchi H , Manaka H , et al.   Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study . Diabetes Care . 1999;22:920–924
  9. DECODE study group  . Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe . Lancet . 1999;354:617–621
  10. Home P , Kurtzhals P . Insulin detemir: from concept to clinical experience . Expert Opin. Pharmacother. . 2006;7:325–343
  11. Bolli GB , Owens DR . Insulin glargine . Lancet . 2000;356:443–445
  12. Havelund S , Plum A , Ribel U , et al.   The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin . Pharm. Res. . 2004;21:1498–1504
  13. Kurtzhals P . Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir . Int. J Obes. Relat. Metab. Disord. . 2004;28(Suppl. 2):S23–S28
  14. Kurtzhals P , Schaffer L , Sorensen A , et al.   Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use . Diabetes . 2000;49:999–1005
  15. Shukla A , Grisouard J , Ehemann V , et al.   Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines . Endocr. Relat. Cancer . 2009;16:429–441
  16. Lepore M , Pampanelli S , Fanelli C , et al.   Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro . Diabetes . 2000;49:2142–2148
  17. Plank J , Bodenlenz M , Sinner F , et al.   A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir . Diabetes Care . 2005;28:1107–1112
  18. Heise T , Nosek L , Ronn BB , et al.   Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes . Diabetes . 2004;53:1614–1620
  19. Klein O , Lynge J , Endahl L , et al.   Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes . Diabetes Obes. Metab. . 2007;9:290–299
  20. Kolendorf K , Ross GP , Pavlic-Renar I , et al.   Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes . Diabet. Med. . 2006;23:729–735
  21. Bartley PC , Bogoev M , Larsen J , Philotheou A . Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial . Diabet. Med. . 2008;25:442–449
  22. Hermansen K , Fontaine P , Kukolja KK , et al.   Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes . Diabetologia . 2004;47:622–629
  23. Russell-Jones D , Simpson R , Hylleberg B , et al.   Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen . Clin Ther . 2004;26:724–736
  24. Centers for Disease Control  . CDC fact sheet 2007 . http://www.cdc.gov/diabetes/pubs/factsheet07.htm (accessed December 16, 2009).
  25. Khan LK , Sobush K , Keener D , et al.   Recommended community strategies and measurements to prevent obesity in the United States . MMWR. Recomm. Rep. . 2009;58:1–26
  26. Gregg EW , Cheng YJ , Narayan KM , et al.   The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976–2004 . Prev. Med. . 2007;45:348–352
  27. Wild S , Roglic G , Green A , et al.   Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 . Diabetes Care . 2004;27:1047–1053
  28. Hossain P , Kawar B , El Nahas M . Obesity and diabetes in the developing world–a growing challenge . N. Engl. J Med. . 2007;356:213–215
  29. Marcovecchio M , Mohn A , Chiarelli F . Type 2 diabetes mellitus in children and adolescents . J. Endocrinol. Invest. . 2005;28:853–863
  30. Zeitler P . Update on nonautoimmune diabetes in children . J. Clin. Endocrinol. Metab. . 2009;94:2215–2220
  31. Schuster DP . Changes in physiology with increasing fat mass . Semin. Pediatr. Surg. . 2009;18:126–135
  32. Brod M , Kongso JH , Lessard S , Christensen TL . Psychological insulin resistance: patient beliefs and implications for diabetes management . Qual. Life Res. . 2009;18:23–32
  33. Garvey WT , Olefsky JM , Griffin J , et al.   The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus . Diabetes . 1985;34:222–234
  34. Li Y , Xu W , Liao Z , et al.   Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function . Diabetes Care . 2004;27:2597–2602
  35. Bretzel RG , Nuber U , Landgraf W , et al.   Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial . Lancet . 2008;371:1073–1084
  36. Holman RR , Thorne KI , Farmer AJ , et al.   Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes . N. Engl. J Med. . 2007;357:1716–1730
  37. Owens DR , Cozma LS , Luzio SD . Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide . Diabetes Nutr. Metab. . 2002;15:19–27
  38. Blonde L , Merilainen M , Karwe V , et al.   Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE study . Diabetes Obes. Metab. . 2009;11:623–631
  39. Russell-Jones D , Khan R . Insulin-associated weight gain in diabetes–causes, effects and coping strategies . Diabetes Obes. Metab. . 2007;9:799–812
  40. Polonsky WH , Anderson BJ , Lohrer PA , et al.   Insulin omission in women with IDDM . Diabetes Care . 1994;17:1178–1185
  41. Bryden KS , Neil A , Mayou RA , et al.   Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes . Diabetes Care . 1999;22:1956–1960
  42. Herpertz S , Albus C , Wagener R , et al.   Comorbidity of diabetes and eating disorders. Does diabetes control reflect disturbed eating behavior? . Diabetes Care . 1998;21:1110–1116
  43. Eeg-Olofsson K , Cederholm J , Nilsson PM , et al.   Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients . Diabetologia . 2009;52:65–73
  44. Anderson JW , Konz EC . Obesity and disease management: effects of weight loss on comorbid conditions . Obes. Res. . 2001;9(Suppl. 4):326S–334S
  45. Heise T , Pieber TR . Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies . Diabetes Obes. Metab. . 2007;9:648–659
  46. Riddle MC , Rosenstock J , Gerich J , on behalf of the INsulin Glargine 4002 Study Investigators  . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients . Diabetes Care . 2003;26:3080–3086
  47. Riddle MC . The Treat-to-Target Trial and related studies . Endocr. Pract. . 2006;12(Suppl. 1):71–79
  48. Raslova K , Bogoev M , Raz I , et al.   Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes . Diabetes Res Clin Pract. . 2004;66:193–201
  49. Hermansen K , Davies M , Derezinski T , et al.   A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes . Diabetes Care . 2006;29:1269–1274
  50. Philis-Tsimikas A , Charpentier G , Clauson P , et al.   Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes . Clin Ther . 2006;28:1569–1581
  51. Rašlová K , Tamer SC , Clauson P , Karl D . Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index . Clin Drug Investig. . 2007;27:279–285
  52. Philis-Tsimikas A . Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes . Patient Prefer. Adherence . 2008;2:323–332
  53. Rosenstock J , Davies M , Home PD , et al.   A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes . Diabetologia . 2008;51:408–416
  54. Hollander P , Cooper J , Bregnhøj J , Pedersen CB . A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes . Clin Ther . 2008;30:1976–1987
  55. Devries JH , Nattrass M , Pieber TR . Refining basal insulin therapy: what have we learned in the age of analogues? . Diabetes Metab. Res. Rev. . 2007;23:441–454
  56. Koenen C . How do detemir and glargine compare when added to oral agents in insulin-naive patients with type 2 diabetes mellitus? . Nat. Clin. Pract. Endocrinol. Metab. . 2008;4:E1
  57. Le Floch JP , Levy M , Mosnier-Pudar H , et al.   Comparison of once-versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT) . Diabetes Care . 2009;32:32–37
  58. Fontaine P , Gin H , Pinget M , et al.   Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE . Adv. Ther. . 2009;26:535–551
  59. Bruce DG , Chisholm DJ , Storlien LH , Kraegen EW . Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes . Diabetes . 1988;37:736–744
  60. Davies M , Storms F , Shutler S , et al.   Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine . Diabetes Care . 2005;28:1282–1288
  61. Davies M , Lavalle-Gonzalez F , Storms F , Gomis R . Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial . Diabetes Obes. Metab. . 2008;10:387–399
  62. Meneghini L , Koenen C , Weng W , Selam J-L . The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes–results of the randomized, controlled PREDICTIVE™ 303 study . Diabetes Obes. Metab. . 2007;9:902–913
  63. Selam JL , Koenen C , Weng W , Meneghini L . Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study . Curr. Med. Res. Opin. . 2008;24:11–20
  64. Hordern SV , Wright JE , Umpleby AM , et al.   Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp . Diabetologia . 2005;48:420–426
  65. Hennige AM , Sartorius T , Tschritter O , et al.   Tissue selectivity of insulin detemir action in vivo . Diabetologia . 2006;49:1274–1282
  66. Tschritter O , Hennige AM , Preissl H , et al.   Cerebrocortical beta activity in overweight humans responds to insulin detemir . PLoS ONE . 2007;2:e1196

PII: S1751-9918(10)60007-1

doi: 10.1016/S1751-9918(10)60007-1

Primary Care Diabetes
Volume 4 , Pages S31-S42 , April 2010

Article Tools